Literature DB >> 6285218

Long term survival among patients with malignant brain tumors.

A N Lieberman, S H Foo, J Ransohoff, A Wise, A George, W Gordon, R Walker.   

Abstract

Eight of 57 patients (14%) with malignant astrocytomas lived at least 2 years. The mean survival time was 143 weeks (range, 104 to 250 weeks). All of the patients were treated with operation, radiation, and chemotherapy. Four of the 8 patients died because of tumor recurrence, 1 died from a second primary tumor, 2 died of cases unrelated to the tumor, and 1 is still alive. Diffuse cortical dysfunction associated with cortical atrophy that could not be related to tumor regrowth and was not explained by focal deficits, psychotic of depressive thought disorders, metabolic or endocrine abnormalities, or hydrocephalus developed in the 3 longest-surviving patients. The diffuse dysfunction was initially apparent only through psychometric testing, but eventually became so disabling as to result in 2 of the 3 patients retiring from work. Although small, but gratifying, gains have been made in the treatment of patients with malignant brain tumors, accompanying these gains have been problems of a magnitude that is only now beginning to be appreciated.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6285218     DOI: 10.1227/00006123-198204000-00006

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  13 in total

1.  Estimation of tumor volume with fuzzy-connectedness segmentation of MR images.

Authors:  Gul Moonis; Jianguo Liu; Jayaram K Udupa; David B Hackney
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

2.  Cancer treatment - objectives and quality of life issues.

Authors:  Farhat Aziz Khan; Shad Salim Akhtar; Muhammad Kamil Sheikh
Journal:  Malays J Med Sci       Date:  2005-01

Review 3.  Indications for Treatment: Is Observation or Chemotherapy Alone a Reasonable Approach in the Management of Low-Grade Gliomas?

Authors:  Lauren R Schaff; Andrew B Lassman
Journal:  Semin Radiat Oncol       Date:  2015-02-23       Impact factor: 5.934

4.  Quality of life in brain tumor patients.

Authors:  A R Giovagnoli; M Tamburini; A Boiardi
Journal:  J Neurooncol       Date:  1996-10       Impact factor: 4.130

Review 5.  Long-term survival in patients with supratentorial glioblastoma.

Authors:  M Salvati; L Cervoni; M Artico; R Caruso; F M Gagliardi
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

Review 6.  Effect of age on treatment decisions in low-grade glioma.

Authors:  C J Vecht
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-12       Impact factor: 10.154

7.  Cognitive impairment and quality of life in long-term survivors of malignant brain tumors.

Authors:  A R Giovagnoli; A Boiardi
Journal:  Ital J Neurol Sci       Date:  1994-12

8.  Single photon emission computed tomography in long-term survivors of adult brain tumours.

Authors:  K P Ebmeier; K Booker; A Gregor; A Cull; N Dougall; R Sellar; G M Goodwin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

9.  Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History Study.

Authors:  James L Rogers; Elizabeth Vera; Alvina Acquaye; Nicole Briceno; Varna Jammula; Amanda L King; Heather Leeper; Martha M Quezado; Javier Gonzalez Alarcon; Lisa Boris; Eric Burton; Orieta Celiku; Anna Choi; Alexa Christ; Sonja Crandon; Ewa Grajkowska; Nicole Leggiero; Nicole Lollo; Marta Penas-Prado; Jennifer Reyes; Christine Siegel; Brett J Theeler; Michael Timmer; Kathleen Wall; Jing Wu; Kenneth Aldape; Mark R Gilbert; Terri S Armstrong
Journal:  Neurooncol Pract       Date:  2021-04-10

10.  Vidarabin-monophosphate, BCNU, VM26--an in vitro comparative study of active agents in the treatment of malignant human brain tumours.

Authors:  U Bogdahn; J Zapf; H Weber; G Dünisch; H G Löbering; R Martin; H G Mertens
Journal:  Br J Cancer       Date:  1987-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.